MedTrace Logo

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

NCT04097925 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-06

Study results available
· View outcomes & findings →

Summary

This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.

Conditions

Interventions

DRUG

Doravirine

Doravirine 100 mg tablet

DRUG

Descovy

Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet

Sponsors & Collaborators

  • Institut d'Investigació Biomèdica de Bellvitge

    collaborator OTHER

  • Hospital Universitari de Bellvitge

    collaborator OTHER

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    lead OTHER

Principal Investigators

  • Daniel Podzamczer Palter, PhD Chief · Hospital Universitari de Bellvitge

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2020-08-24
Completion
2020-08-24
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04097925 on ClinicalTrials.gov